Evidence map›Paper›PMID 39864041›Full record

ArticleCalcified tissue international2025

18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia.

Macarena Jimenez, Aaron J Sheppard, Rodrigo Jaimovich, Natalia Covarrubias, Diego Jordan, Juan Carlos Quintana, Oscar Contreras, Danisa Ivanovic Zuvic, Anette Madison, Babak Saboury and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Macarena Jimenez *Endocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile.
Aaron J Sheppard *Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
Rodrigo JaimovichRadiology and Nuclear Medicine Department, School of Medicine, Universidad Católica de Chile, Santiago, Chile.
Natalia CovarrubiasRadiology and Nuclear Medicine Department, School of Medicine, Universidad Católica de Chile, Santiago, Chile.
Diego JordanRadiology and Nuclear Medicine Department, School of Medicine, Universidad Católica de Chile, Santiago, Chile.
Juan Carlos QuintanaRadiology and Nuclear Medicine Department, School of Medicine, Universidad Católica de Chile, Santiago, Chile.
Oscar ContrerasRadiology and Nuclear Medicine Department, School of Medicine, Universidad Católica de Chile, Santiago, Chile.
Danisa Ivanovic ZuvicEndocrinology Department, Hospital del Salvador, Santiago, Chile.
Anette MadisonEndocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile.
Babak SabourySkeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
Michael T CollinsSkeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
Pablo FlorenzanoEndocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile. pflorenz@uc.cl.ORCID 0000-0001-5936-3146

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked hypophosphatemia (XLH) is a rare metabolic disorder characterized by elevated FGF23 and chronic hypophosphatemia, leading to impaired skeletal mineralization and enthesopathies that are associated with pain, stiffness, and diminished quality of life. The natural history of enthesopathies in XLH remains poorly defined, partly due to absence of a sensitive quantitative tool for assessment and monitoring. This study investigates the utility of 18F-NaF PET/CT scans in characterizing enthesopathies in XLH subjects. In 19 adult XLH subjects, enthesopathy burden was assessed by quantifying calcified sites on CT and 18F-NaF PET uptake at 16 common tendon/ligament insertion locations. Parameters obtained were (1) number of enthesopathy sites, (2) characterization of each site as CT-positive (CT +) and/or PET-positive (PET +), (3) a semiquantitative score based on severity of affected enthesopathies (CT-score

Indexed as

EnthesopathyFamilial Hypophosphatemic RicketsPositron Emission Tomography Computed TomographySodium FluorideAdultAgedFemaleFibroblast Growth Factor-23Fluorine RadioisotopesHumansMaleMiddle AgedYoung AdultFGF23 protein, humanFibroblast Growth Factor-23Fluorine RadioisotopesSodium FluorideEnthesopathyExtra-skeletal calcificationsFibroblast growth factor 23 (FGF23)Osteomalacia and ricketsX‐linked hypophosphatemia (XLH)

Identifiers

PMID39864041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.